<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="1" ids="16247">Phospholipids</z:chebi> are abundantly represented within the <z:mp ids='MP_0008912'>nervous</z:mp> system </plain></SENT>
<SENT sid="1" pm="."><plain>Aim of our study was to evaluate the presence and fine specificity of anti <z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibodies (aPLAb) among patients with <z:e sem="disease" ids="C1136085" disease_type="Neoplastic Process" abbrv="">monoclonal gammopathy</z:e> associated <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty nine percent of these patients had high titers of aPLAb, mostly associated with low levels of anti beta2 <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I, which suggests different antibody specificity compared to patients with anti <z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome </plain></SENT>
<SENT sid="3" pm="."><plain>Further 6/48 patients with dysimmune <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> without <z:e sem="disease" ids="C1136085" disease_type="Neoplastic Process" abbrv="">monoclonal gammopathy</z:e> had positive aPLAb titers </plain></SENT>
<SENT sid="4" pm="."><plain>APLAb strongly cross-reacted with sulfatide </plain></SENT>
<SENT sid="5" pm="."><plain>These findings suggest an adjuntive role of aPLAb on nerve damage and may help to better understand the nerve binding properties of anti-sulfatide antibodies </plain></SENT>
</text></document>